Form 4: Aprea Therapeutics Director Sells Shares to Cover Insufficient Cash Position

Director Marc Duey sold 6,462 shares of Aprea Therapeutics common stock on October 18, 2024, due to an insufficient cash position in his brokerage account, resulting in a short-swing transaction requiring him to pay the company $1,558.05.

Summary

• On October 18, 2024, Marc Duey, a director of Aprea Therapeutics, sold 6,462 shares of the company's common stock at $4.578 per share.
• The sale was triggered by an insufficient cash position in Duey's brokerage account.
• The sale was matchable under Section 16(b) of the Securities Exchange Act of 1934 with previous purchases.
• Specifically, 190 shares matched a purchase of 190 shares at $2.5837 on October 14, 2024, and 6,272 shares matched a purchase of 30,000 shares at $4.39 per share on October 16, 2024.
• Duey has agreed to pay Aprea Therapeutics $1,558.05, representing the profit realized from the short-swing transaction.
• Following the transaction, Duey directly owns 233,651 shares of Aprea Therapeutics common stock.
• Duey's spouse indirectly owns 602 shares, but Duey disclaims beneficial ownership of these shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the director's share sale being triggered by an insufficient cash position and the resulting short-swing transaction. While the amount is relatively small, it raises questions about the director's financial planning and could erode investor confidence.

Negatives

• A director had to sell shares due to an insufficient cash position, which could be perceived negatively by investors.
• The sale triggered a short-swing transaction, requiring the director to return profits to the company.

Risks

• The director's financial situation may raise concerns about their confidence in the company.
• Short-swing transactions can create negative publicity and potential legal scrutiny.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

Industry Context

Form 4 filings are routine disclosures for corporate insiders, but sales due to personal financial reasons can sometimes raise concerns among investors, especially if the insider is a director.

Comparison to Industry Standards

• It's common for directors to trade company stock, but sales triggered by personal financial issues are less frequent.
• Comparing this transaction to other Form 4 filings within the biotechnology industry could provide context on the typical trading activity of insiders.

Stakeholder Impact

• Shareholders may react negatively to the director's sale of shares due to personal financial reasons.
• The company may face scrutiny regarding insider trading policies and procedures.

Key Dates